Table 1.
Characteristics of included studies
| StudY | Year | No.of cases | Age(mean range) | Initial Tumor Size | Histologic SubtYpe |
Equipment (MRI,C-ESM)and Magnet Strength (T) | Duration of the patients (year. month) | pCR rate (%) |
Definition of pCR | Contrast Material (MRI,CESM,d-ose) |
CE-MRIor CESM used |
The research type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| De Los Santos14 | 2013 | 746 | 49 (20–86） | T1—4 | IDC,ILC | GE,3/1.5T | 2002.01–2011.02 | 23.99 | No residual | NR | CE-MRI | retrospective |
| Chen16 | 2008 | 51 | 49.5 (31–77) | T2—4 | NR | Philips,1.5T | NR | 54.9 | No invasive | 0.1 cc/kg | CE-MRI | retrospective |
| Nicoletto17 | 2008 | 26 | 47 (30–57) | T2—4 | IDC,ILC | NR | 2001.03–2003.06 | 23.08 | No residual | NR | CE-MRI | prospective |
| Choi, J.H18 | 2010 | 29 | 45.1 (24–63) | T2—4 | IDC,ILC | NR | 2004.12–2008.03 | 24.17 | No residual | NR | CE-MRI | prospective |
| Dose—Schwarz19 | 2010 | 46 | 50 (30–66) | T2—4 | NR | NR | NR | 10.87 | No residual | NR | CE-MRI | prospective |
| Fangberget20 | 2011 | 22 | 50.7 (37–72) | T2—4 | IDC,ILC | Siemens,1.5T | 2007.04–2008.10 | 36.36 | No invasive | 0.1 mmol/kg | CE-MRI | prospective |
| Park21 | 2011 | 32 | 45 (28–67) | NR | IDC | Siemens,1.5T | 2006.08–2008.05 | 25.00 | No invasive | 0.1 mmol/kg | CE-MRI | retrospective |
| Hayashi, Y22 | 2013 | 264 | 51 (23–71) | T1—4 | IDC | Philips,1.5T | 2003.02–2008.06 | 37.12 | No invasive | NR | CE-MRI | prospective |
| Ko, E.S23 | 2013 | 166 | 44 (23–72) | T2—4 | IDC,ILC | Philips,3T | 2007.04–2010.12 | 24.09 | No invasive | 0.1 mmol/kg | CE-MRI | retrospective |
| Williams24 | 2013 | 87 | 50 (25–83) | T2—4 | IDC,ILC | Fairfield,1.5T | 2004.01–2009.11 | 25.29 | No residual | 0.1 mmol/kg | CE-MRI | retrospective |
| Choi, BB25 | 2015 | 98 | 50 (29–81) | NR | IDC,ILC | Philips,3/1.5T | 2006–2011 | 17.35 | No invasive | 0.2 mmol/kg | CE-MRI | prospective |
| Diguisto26 | 2015 | 102 | 48.5 | NR | IDC,ILC | Siemens,1.5T | 2008.01–2011.12 | 29.41 | No residual | NR | CE-MRI | prospective |
| Lee, M.C27 | 2015 | 39 | 46.9 (24–64） | T1—4 | NR | NR | 2008–2012 | 28.21 | No invasive | NR | CE-MRI | prospective |
| Vriens28 | 2016 | 149 | NR | NR | NR | >1.5T | 2006.02–2009.04 | 16.78 | No invasive | NR | CE-MRI | prospective |
| Fukuda29 | 2016 | 265 | 49.9 (25–78) | T2—4 | NR | GE,1.5T | 2005.01–2007.12 | 7.17 | No invasive | 0.2 mmol/kg | CE-MRI | retrospective |
| Weber,JJ31 | 2017 | 129 | 50.8(27–80) | T1—4 | NR | Milwaukee,3/1.5T | 2014.06–2015.08 | 31 | No residual | 0.1 mmol/kg | CE-MRI | prospective |
| ElSaid32 | 2017 | 21 | 50 (30–77） | T3—4 | IDC,ILC,other | GE Healthcare | NR | 28.5 | No residual | 1.5 ml/kg | CESM | prospective |
| Moustafa33 | 2019 | 42 | NR | NR | IDC,ILC,other | GE Seno graphe | NR | 92.85 | No residual | NR | CESM | prospective |
| Iotti34 | 2017 | 46 | 54 (33–72） | T2—4 | IDC,ILC,other | GE,1.5T,GE Healthcare | 2012.10–2014.12 | 17 | No residual | NR | CE-MRI/CESM | prospective |
| Patel37 | 2018 | 65 | 52.7 (30–76） | T1—4 | IDC,ILC,other | GE,3.0T,GE Healthcare | NR | 30.76 | No residual | NR,1.5 ml/kg | CE-MRI/CESM | prospective |
| Barra35 | 2018 | 33 | 45(22-76) | NR | IDC,ILC,other | GE,1.5T,GE Healthcare | 2015.08–2017.12 | 24.2 | No residual | 0.1 mmol/kg,NR | CE-MRI/CESM | prospective |
| Barraa36 | 2017 | 8 | 46.41(22-76) | NR | NR | GE Healthcare | 2011–2013 | 75 | No residual | 1–2 mL/kg | CESM | retrospective |
| Trecate15 | 1999 | 30 | NR | T4/LABC | NR | Siemens,1.5T | 1995.11–1998.04 | 13.33 | No residual | 0.1 mmol/kg | CE-MRI | prospective |
| BhattacharYYa30 | 2008 | 32 | 42.7 (24–60) | T2—3 | NR | GE,1.5T | NR | 15.63 | No invasive | 16 mmol/kg | CE-MRI | prospective |
NR, not reported; pCR, pathological complete response.
Quality assessment
a
a study of the same author but different publication year;